PL1648427T3 - Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM - Google Patents
Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgMInfo
- Publication number
- PL1648427T3 PL1648427T3 PL04752450T PL04752450T PL1648427T3 PL 1648427 T3 PL1648427 T3 PL 1648427T3 PL 04752450 T PL04752450 T PL 04752450T PL 04752450 T PL04752450 T PL 04752450T PL 1648427 T3 PL1648427 T3 PL 1648427T3
- Authority
- PL
- Poland
- Prior art keywords
- low dose
- antibody treatment
- igm antibody
- demyelinating disorders
- demyelinating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47123503P | 2003-05-16 | 2003-05-16 | |
| PCT/US2004/015436 WO2004110355A2 (en) | 2003-05-16 | 2004-05-17 | Compositions and methods including a recombinant human mab that promotes cns remyelination |
| EP04752450.9A EP1648427B1 (en) | 2003-05-16 | 2004-05-17 | Low dose IgM antibody treatment of demyelinating disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1648427T3 true PL1648427T3 (pl) | 2014-05-30 |
Family
ID=33551425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04752450T PL1648427T3 (pl) | 2003-05-16 | 2004-05-17 | Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8460665B2 (pl) |
| EP (1) | EP1648427B1 (pl) |
| JP (1) | JP2007505157A (pl) |
| AU (2) | AU2004247021A1 (pl) |
| CA (2) | CA2967294C (pl) |
| ES (1) | ES2451993T3 (pl) |
| PL (1) | PL1648427T3 (pl) |
| WO (1) | WO2004110355A2 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010509235A (ja) * | 2006-11-03 | 2010-03-25 | ノースウェスタン ユニバーシティ | 多発性硬化症の治療 |
| WO2009104100A2 (en) * | 2008-02-19 | 2009-08-27 | Patrys Limited | Antibody combinations, and methods of making and using same |
| NZ624752A (en) * | 2010-10-19 | 2015-11-27 | Mayo Foundation | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| US9150867B2 (en) | 2011-04-28 | 2015-10-06 | Mayo Foundation For Medical Education And Research | DNA aptamers for promoting remyelination |
| US20150104460A1 (en) | 2012-04-17 | 2015-04-16 | Mayo Foundation For Medical Education And Research | Human Antibodies and Specific Binding Sequences Thereof for use in Stroke and Ischemia or Ischemic Conditions |
| EP3215190A4 (en) | 2014-11-07 | 2018-10-31 | Mayo Foundation for Medical Education and Research | Treatment of neonatal hypoxia including impairments or effects thereof |
| US11999778B2 (en) | 2016-05-13 | 2024-06-04 | The Board Of Regents Of The University Of Texas System | VH4 antibodies and compositions comprising the same |
| EP3401682A1 (en) * | 2017-05-09 | 2018-11-14 | Université de Nantes | Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system |
| US12037590B2 (en) | 2018-12-06 | 2024-07-16 | Mayo Foundation For Medical Education And Research | Short DNA aptamers and methods for promoting remyelination |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| DE3825429C2 (de) | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US5591629A (en) * | 1994-04-29 | 1997-01-07 | Mayo Foundation For Medical Education & Research | Monoclonal antibodies which promote central nervous system remyelination |
| EP2287190B1 (en) | 2000-05-10 | 2014-12-17 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| JP2008127346A (ja) | 2006-11-22 | 2008-06-05 | Toshitsu Kagaku Kenkyusho:Kk | 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬 |
-
2004
- 2004-05-17 ES ES04752450.9T patent/ES2451993T3/es not_active Expired - Lifetime
- 2004-05-17 WO PCT/US2004/015436 patent/WO2004110355A2/en not_active Ceased
- 2004-05-17 EP EP04752450.9A patent/EP1648427B1/en not_active Expired - Lifetime
- 2004-05-17 AU AU2004247021A patent/AU2004247021A1/en not_active Abandoned
- 2004-05-17 US US10/557,115 patent/US8460665B2/en not_active Expired - Fee Related
- 2004-05-17 PL PL04752450T patent/PL1648427T3/pl unknown
- 2004-05-17 JP JP2006533147A patent/JP2007505157A/ja active Pending
- 2004-05-17 CA CA2967294A patent/CA2967294C/en not_active Expired - Lifetime
- 2004-05-17 CA CA2525917A patent/CA2525917C/en not_active Expired - Lifetime
-
2010
- 2010-05-25 AU AU2010202111A patent/AU2010202111B2/en not_active Ceased
-
2013
- 2013-03-07 US US13/788,529 patent/US8968735B2/en not_active Expired - Lifetime
-
2015
- 2015-01-23 US US14/603,553 patent/US9751943B2/en not_active Expired - Fee Related
-
2017
- 2017-09-01 US US15/693,803 patent/US20180179277A1/en not_active Abandoned
-
2019
- 2019-09-23 US US16/578,649 patent/US20200247883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180179277A1 (en) | 2018-06-28 |
| CA2525917C (en) | 2017-07-04 |
| AU2010202111A1 (en) | 2010-06-17 |
| US20070086999A1 (en) | 2007-04-19 |
| EP1648427A4 (en) | 2007-04-11 |
| US20130309240A1 (en) | 2013-11-21 |
| CA2525917A1 (en) | 2004-12-23 |
| EP1648427A2 (en) | 2006-04-26 |
| WO2004110355A3 (en) | 2006-05-18 |
| AU2010202111B2 (en) | 2012-11-15 |
| WO2004110355A2 (en) | 2004-12-23 |
| AU2004247021A1 (en) | 2004-12-23 |
| US20150299316A1 (en) | 2015-10-22 |
| US8968735B2 (en) | 2015-03-03 |
| ES2451993T3 (es) | 2014-03-28 |
| US20200247883A1 (en) | 2020-08-06 |
| CA2967294C (en) | 2020-04-28 |
| CA2967294A1 (en) | 2004-12-23 |
| EP1648427B1 (en) | 2013-12-18 |
| JP2007505157A (ja) | 2007-03-08 |
| US9751943B2 (en) | 2017-09-05 |
| US8460665B2 (en) | 2013-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI347951B (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| SI2359856T1 (sl) | Formulacija humanih protiteles za zdravljenje motenj, povezanih s TNF-alfa | |
| IL173386A0 (en) | Use of adcc-optimized antibodies for treating weak patients | |
| EP1482972A4 (en) | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES | |
| IL212419A0 (en) | Methods of administering anti-tnf antibodies | |
| EP1578988A4 (en) | TNF-ALPHA VARIANT-BASED PROTEIN FOR TREATMENT OF TNF-ALPHA ASSOCIATED DISORDERS | |
| PL378108A1 (pl) | Leczenie łączone do terapii zapalnych zaburzeń immunologicznych | |
| IL174232A0 (en) | Combinations of drugs for the treatment of neoplasms | |
| PL375532A1 (pl) | Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów | |
| IL169332A0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA200500618B (en) | Combinations of drugs for the treatment of neoplasms | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| EP1658072A4 (en) | Compounds for the Treatment of Neurodegenerative Diseases | |
| AU2003251904A8 (en) | Combinations of drugs for the treatment of neoplasms | |
| EP1549343A4 (en) | PROCESS FOR TREATING NEPHRITIS WITH ANTI-PDGF-DD ANTIBODIES | |
| PL1648427T3 (pl) | Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM | |
| AU2003251875A8 (en) | Combination therapy for the treatment of neoplasms | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| IL175412A0 (en) | Use of specific histones for the treatment of parasitic diseases | |
| ZA200505996B (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| AU2003295504A8 (en) | Development of therapeutics for the treatment of endotoxin-mediated diseases | |
| GB0222282D0 (en) | Therapeutic device for the treatment of symptons caused by diseases | |
| GB0315877D0 (en) | Compounds for the treatment of disease | |
| GB0325986D0 (en) | Inhibitors of a-synuclein aggregation for the treatment of a-synuclein-related diseases | |
| GB0305343D0 (en) | Therapeutic agents for the treatment of bone disorders |